Code WINTER: 20% off everything, 25% off GLPs at · Purgo Labs

Related brand · disclosed
USA Peptide VendorsResearch vendor desk
Purgo LabsWINTER

Try

Metabolic research peptides

Retatrutide

Retatrutide research vials appear frequently in 2025–2026 US catalogs. Documentation quality varies widely between shops.

Updated 2026-11-07
Original illustration for Retatrutide research notes: abstract molecular artwork in orange and teal

Original illustration by USA Peptide Vendors. Artistic, not a structural model.

Chemistry facts

Amino acid sequence · 39 residues
  1. Y1
  2. X2
  3. Q3
  4. G4
  5. T5
  6. F6
  7. T7
  8. S8
  9. D9
  10. Y10
  11. S11
  12. I12
  13. L13
  14. L14
  15. D15
  16. K16
  17. K17
  18. A18
  19. Q19
  20. X20
  21. A21
  22. F22
  23. I23
  24. E24
  25. Y25
  26. L26
  27. L27
  28. E28
  29. G29
  30. G30
  31. P31
  32. S32
  33. S33
  34. G34
  35. A35
  36. P36
  37. P37
  38. P38
  39. S39

Sequence as listed by KEGG, which classifies retatrutide as a modified peptide. X marks a non-standard residue.

CAS number
2381089-83-2
Molecular formula
C221H342N46O68
Molecular weight
4731.34 g/mol
PubChem CID
171390338

Verified 2026-11-09 against KEGG DRUG D12430 and PubChem CID 171390338. Values we could not verify are left out.

How Retatrutide is thought to work

Evidence level: Clinical: published phase 2 trial. See every diagram in the mechanism map library.

Retatrutide mechanism diagramTriple agonist at the GIP, GLP-1 and glucagon receptors. Targets: GIPR, GLP-1R, GCGR. Shared G protein signaling: Gαs → Adenylyl cyclase → cAMP ↑. Effects reported: Calorie intake ↓, Energy expenditure ↑, Weight reduction.Retatrutide mechanism mapTriple agonist at the GIP, GLP-1 and glucagon receptorsRetatrutideLY3437943, acylated peptideGIPRGIP receptor [1]GLP-1RGLP-1 receptor [1]GCGRglucagon receptor [1]Gαs[1]Adenylyl cyclase[1]cAMP ↑[1]Calorie intake ↓GIPR + GLP-1R, mice [1]Energy expenditure ↑GCGR, mice [1]Weight reductionphase 2 trial [2]Evidence: Clinical: published phase 2 trial. Numbers in brackets refer to the citedsources.usapeptidevendors.com · Research Use OnlyRECEPTORS (AGONIST AT ALL THREE)SHARED G PROTEIN SIGNALINGEFFECTS REPORTED
Investigational compound. Clinical findings apply to the trial formulation, not to research-catalog vials. Open SVG
  1. Coskun T et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss. Cell Metab. 2022;34:1234–1247.
  2. Jastreboff AM et al. Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial. N Engl J Med. 2023;389:514–526.

Research context

UPV tracks which vendors publish third-party assays for retatrutide-labeled research materials and how openly they display stock status.

Buyer notes

  • Demand lot-specific assays rather than category-level PDFs
  • Confirm cold-chain or packing claims if your lab requires them
  • Treat “research strength” marketing language as non-clinical

Related USA vendors

Purgo Labs — OpenFile clear

US catalog with lot notes that usually sit next to the buy button

Lumen Forge Bio — OpenFile hold

Fast restocks, short public history

Harbor Peptide Supply — OpenFile conditional

Broad grid, uneven public files

FAQ

Are retatrutide research vials the same as pharmacy products?

No. Research catalog materials are not pharmacy-dispensed products and are not for human consumption.

← All compounds · Mechanism maps · BPC-157 vendor guide · All desk notes